Savara Inc. (NASDAQ:SVRA) Q2 2020 Earnings Conference Call - Final Transcript
Aug 06, 2020 • 04:30 pm ET
the patients syndrome.
Given enrolled patients in IMPALA 2 with similar disease severity, as was an IMPALA. In IMPALA, there was a noted improvement on the - surface change after a whole lung lavage. However, the improvement was for limited duration, and the patients disease progress. We anticipate that to change in IMPALA 2.
Thank you, Jason. Are there any other questions?
No, there are no more questions in the queue.
Okay. Okay. Thank you. Thank you, Jason, and thank you everybody for taking the time to join our call. I appreciate it. Take care.
[Operator Closing Remarks]